S&P Biotech ETF (CURE) – Global X ETFs Australia

CURE


S&P Biotech ETF

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Structural Tailwinds

The cost of genomic sequencing has dropped from nearly USD$100mm per genome in 2002 to less than USD$1,000 in 2020. Adoption has continued to rise, as costs plummet.1

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

1 National Human Genome Research Institute, Nov 2021

Product Information As of 22 Feb 2024

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 22 Feb 2024

NAV/Unit (A$) 49.19010000
Currency (NAV) AUD
Shares Outstanding 864,012
AUM (A$) 42,500,863.45
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 31 Jan 2024

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 22 Feb 2024

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month 6.55% 6.53% 0.02% 0.06%
3 Months 29.06% 29.13% -0.07% 0.09%
1 Year 17.01% 17.91% -0.90% 1.44%
3 Year p.a. -9.72% -9.47% -0.25% 0.98%
5 Year p.a. 3.37% 3.80% -0.43% 0.85%
10 Year p.a. -- -- -- --
Since Inception p.a. 3.98% 4.40% -0.42% 0.84%

Top Holdings As of 23 Feb 2024

Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
2.47 CYTOKINETICS INC BBBSBJ5 75.59 9,084 1,049,136
2.47 IOVANCE BIOTHERA BF0DMK7 15.94 43,042 1,048,265
1.88 RECURSION PHAR-A BM9FJ13 15.00 34,887 799,549
1.83 VIKING THERAPEUT BQQG1V1 35.66 14,259 776,892
1.73 KARUNA THERAPEUT BJMLSD2 319.38 1,507 735,379
1.72 SAREPTA THERAPEU B8DPDT7 134.78 3,559 732,898
1.59 BIOHAVEN LTD BPLZ7S5 47.33 9,369 677,517
1.50 ARDELYX INC BN89V40 8.82 47,457 639,527
1.49 CRISPR THERAPEUT BDHF4K6 86.19 4,799 631,972
1.45 VAXCYTE INC BKPVGH6 73.87 5,466 616,919
1.41 BEAM THERAPEUTIC BK6L288 33.54 11,721 600,645
1.38 MODERNA INC BGSXTS3 99.44 3,857 586,005
1.37 ARROWHEAD PHARMA BYQBFJ8 30.20 12,596 581,206
1.36 NATERA INC BYQRG48 71.15 5,327 579,093
1.36 VERTEX PHARM 2931034 426.78 885 577,082
1.36 AKERO THERAPEUTI BK7Y2V9 24.21 15,589 576,638
1.35 ULTRAGENYX PHARM BJ62Z18 48.88 7,656 571,773
1.33 MADRIGAL PHARMAC BD59BS7 248.53 1,487 564,651
1.32 AMICUS THERAPEUT B19FQ48 13.40 27,441 561,817
1.32 ACADIA PHARMACEU 2713317 24.85 14,764 560,558
1.32 ABBVIE INC B92SR70 176.75 2,075 560,361
1.32 REVOLUTION MEDIC BL71K91 29.05 12,597 559,118
1.31 NUVALENT INC-A BMVBZD3 83.23 4,384 557,495
1.29 BLUEPRINT MEDICI BWY52P3 86.00 4,187 550,163
1.29 IRONWOOD PHARMAC B3MZ6K5 14.86 24,212 549,718
1.29 ROIVANT SCIENCES BMW4NZ9 11.36 31,511 546,929
1.28 REGENERON PHARM 2730190 964.89 369 543,995
1.27 NEUROCRINE BIOSC 2623911 133.37 2,641 538,167
1.24 ALKERMES PLC B3P6D26 28.91 11,978 529,082
1.24 INCYTE CORP 2471950 60.91 5,663 527,018
1.20 APELLIS PHARMACE BYTQ6X1 67.59 4,938 509,946
1.18 AMGEN INC 2023607 285.18 1,151 501,516
1.17 KRYSTAL BIOTECH BD6JX35 111.96 2,899 495,908
1.15 BRIDGEBIO PHARMA BK1KWG8 33.60 9,525 488,984
1.14 SYNDAX PHARMACEU BN7Q7R7 22.71 13,917 482,895
1.11 CRINETICS PHARMA BDD19F8 36.72 8,428 472,844
1.11 HALOZYME THERAPE 2975098 39.72 7,754 470,571
1.10 TWIST BIOSCIENCE BGKG6G7 38.62 7,922 467,452
1.10 PTC THERAPEUTICS B17VCN9 26.04 11,730 466,691
1.08 INSMED INC 2614487 27.15 11,079 459,580
1.08 BIOMARIN PHARMAC 2437071 89.97 3,333 458,167
1.07 IDEAYA BIOSCIENC BK0VHF6 44.55 6,672 454,145
1.07 ALNYLAM PHARMACE B00FWN1 162.81 1,822 453,231
1.05 EXELIXIS INC 2576941 20.71 14,080 445,526
1.04 INTELLIA THERAPE BYZM6C2 27.18 10,674 443,269
1.04 VERA THERAPEUTIC BL55460 49.00 5,892 441,112
1.03 BIOGEN INC 2455965 222.48 1,294 439,861
1.03 GILEAD SCIENCES 2369174 72.78 3,920 435,902
1.02 EXACT SCIENCES 2719951 59.49 4,786 435,018
1.02 IMMUNOVANT INC BJRFSB7 35.99 7,904 434,629
1.01 IONIS PHARMACEUT BDJ0LS6 43.98 6,362 427,503
1.00 UNITED THERAPEUT 2430412 217.60 1,282 426,223
0.98 NOVAVAX INC BJDQXG4 4.88 55,611 414,640
0.95 TG THERAPEUTICS B828K63 13.44 19,705 404,637
0.90 MORPHIC HOLDING BK8M4J4 35.85 6,995 383,149
0.88 SPRINGWORKS THER BGMGM89 49.11 4,980 373,671
0.85 SAGE THERAPEUTIC BP4GNK9 22.25 10,589 359,977
0.84 ARCELLX INC BPCJ1Q2 60.50 3,862 356,992
0.83 DYNAVAX TECHNOLO BRJZSK0 12.44 18,642 354,326
0.75 ROCKET PHARMACEU BDFKQ07 29.00 7,194 318,756
0.72 CEREVEL THERAPEU BMVMJ12 41.06 4,882 306,272
0.69 PROTHENA CORP PL B91XRN2 26.95 7,156 294,659
0.69 BIOCRYST PHARM 2100362 5.82 32,969 293,170
0.69 CELLDEX THERAPEU BJLV8T9 37.44 5,107 292,141
0.67 DENALI THERAPEUT BD2B4V0 16.83 11,108 285,634
0.66 RHYTHM PHARMACEU BF2YWG4 44.06 4,197 282,536
0.63 VERICEL CORP BSBMN89 48.31 3,613 266,683
0.62 ZENTALIS PHARMAC BMQ5T49 13.95 12,425 264,826
0.61 CATALYST PHARMAC B1G7Q03 13.90 12,151 258,058
0.61 ARCUS BIOSCIENCE BDZT9Y9 19.67 8,584 257,979
0.60 KYMERA THERAPEUT BMPRZV5 40.49 4,103 253,828
0.60 89BIO INC BK1K484 10.59 15,652 253,254
0.57 PROTAGONIST THER BDCBCD8 27.69 5,729 242,377
0.57 CABALETTA BIO IN BK5MWR1 22.19 7,145 242,242
0.56 AGIOS PHARMACEUT BCBVTX1 29.78 5,240 238,422
0.52 ARCTURUS THERAPE BKC9SX3 37.44 3,864 221,036
0.50 VIR BIOTECHNOLOG BK4PZ38 10.30 13,621 214,356
0.50 VERVE THERAPEUTI BNKGXX2 13.32 10,412 211,899
0.49 KEROS THERAPEUTI BM7V485 60.99 2,229 207,711
0.49 MYRIAD GENETICS 2614153 23.10 5,852 206,541
0.49 INHIBRX INC BK1MBC3 38.33 3,525 206,437
0.48 IMMUNITYBIO INC BNSP0B8 5.24 25,525 204,356
0.48 VERACYTE INC BFTWZY0 24.34 5,445 202,492
0.46 DYNE THERAPEUTIC BN15WD1 22.41 5,659 193,763
0.45 REPLIMUNE GROUP BDDVW37 7.95 15,822 192,185
0.45 MIRUM PHARMACEUT BJDX8Y8 28.22 4,451 191,913
0.45 VIRIDIAN THERAPE BMDH2B6 17.99 6,914 190,043
0.44 SANA BIOTECHNOLO BMFJJ97 8.09 15,098 186,620
0.42 RELAY THERAPEUTI BN2R582 10.57 11,183 180,602
0.42 DAY ONE BIOPHARM BLB0YH0 14.56 8,070 179,525
0.41 TRAVERE THERAPEU BLFGJD5 7.86 14,652 175,958
0.40 GERON CORP 2370381 1.97 56,987 171,527
0.38 AVID BIOSERVICES BFMZ4W7 7.99 13,151 160,545
0.37 KURA ONCOLOGY IN BYZD465 19.59 5,220 156,241
0.36 XENCOR INC BGCYWN8 24.39 4,134 154,054
0.36 MANNKIND CORP BF081J4 3.59 27,899 153,029
0.35 AVIDITY BIOSCIEN BMWHPY1 14.54 6,770 150,398
0.35 ADMA BIOLOGICS I B9NSBM2 5.26 18,585 149,362
0.35 EDITAS MEDICINE BZ8FPH3 7.93 12,165 147,393
0.33 ALPINE IMMUNE SC BYX38M1 33.11 2,766 139,927
0.33 CARIBOU BIOSCIEN BNYJR68 6.92 13,152 139,056
0.32 DISC MEDICINE IN BMGJZJ8 64.98 1,375 136,513
0.31 SOLENO THERAPEUT BL6JK96 48.61 1,790 132,944
0.31 COGENT BIOSCIENC BLR6XK8 8.95 9,604 131,330
0.29 UNIQURE NV BJFSR88 6.28 12,723 122,079
0.28 4D MOLECULAR THE BKLXFX5 26.18 2,948 117,920
0.27 DECIPHERA PHARMA BZ1LFB2 15.75 4,816 115,893
0.27 REGENXBIO INC BZ0G875 18.17 4,169 115,738
0.23 KINIKSA PHARMA-A BD0MGM0 19.72 3,307 99,639
0.21 SCHOLAR ROCK HOL BFZQ0L8 15.63 3,716 88,741
0.20 BIOMEA FUSION IN BNKF6N0 16.14 3,508 86,507
0.20 MACROGENICS INC BFDV8K0 17.11 3,268 85,432
0.20 CAREDX INC BP3YM74 8.27 6,569 83,003
0.18 BLUEBIRD BIO INC BBFL7S1 1.18 43,399 78,244
0.18 MIMEDX GROUP INC B1Z3TW5 8.18 6,045 75,551
0.15 ALECTOR INC BJ4LDC4 6.47 6,352 62,792
0.14 ANAVEX LIFE SCIE BYTYP72 5.01 7,720 59,094
0.14 SCILEX HOLDING C BLKFRT9 1.74 21,910 58,248
0.10 RAPT THERAPEUTIC BK5T6R0 9.24 3,159 44,598
Holdings are subject to change.

Sector Breakdown As of 23 Feb 2024

Sector Weight (%)
Health Care 99.8
Other/Cash 0.2

Country Breakdown As of 23 Feb 2024

Country Weight (%)
United States 96.1
Ireland 1.9
Switzerland 1.5
Netherlands 0.3
Other/Cash 0.2

Research

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.
  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.
  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.
  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.
  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top